Albiglutida (Spanish Wikipedia)

Analysis of information sources in references of the Wikipedia article "Albiglutida" in Spanish language version.

refsWebsite

Global rank Spanish rank

4^th place

4^th place

2^nd place

2^nd place

719^th place

759^th place

68^th place

91^st place

1endojournals.org

low place

9,649^th place

54^th place

89^th place

79^th place

179^th place

1pharmazeutische-zeitung.de

8,614^th place

low place

doi.org

dx.doi.org

Liu, J; Li, L; Deng, K; Xu, C; Busse, JW; Vandvik, PO; Li, S; Guyatt, GH et al. (8 de junio de 2017). «Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis». BMJ (Clinical Research Ed.) 357: j2499. PMC 5463186. PMID 28596247. doi:10.1136/bmj.j2499.
Madsbad, S (2015). «Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists». Diabetes, Obesity & Metabolism 18 (4): 317-332. PMC 5064617. PMID 26511102. doi:10.1111/dom.12596.
«Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes». J. Clin. Endocrinol. Metab. 93 (12): 4810-4817. Diciembre de 2008. PMID 18812476. doi:10.1210/jc.2008-1518.

endojournals.org

jcem.endojournals.org

«Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes». J. Clin. Endocrinol. Metab. 93 (12): 4810-4817. Diciembre de 2008. PMID 18812476. doi:10.1210/jc.2008-1518.

europa.eu

ema.europa.eu

«Eperzan: EPAR — Product Information». European Medicines Agency. 4 de agosto de 2017.

forbes.com

Matthew Herper for Forbes. 16 July 2012. Three Lessons From GlaxoSmithKline's Purchase Of Human Genome Sciences

medscape.com

nih.gov

ncbi.nlm.nih.gov

Liu, J; Li, L; Deng, K; Xu, C; Busse, JW; Vandvik, PO; Li, S; Guyatt, GH et al. (8 de junio de 2017). «Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis». BMJ (Clinical Research Ed.) 357: j2499. PMC 5463186. PMID 28596247. doi:10.1136/bmj.j2499.
Madsbad, S (2015). «Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists». Diabetes, Obesity & Metabolism 18 (4): 317-332. PMC 5064617. PMID 26511102. doi:10.1111/dom.12596.
«Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes». J. Clin. Endocrinol. Metab. 93 (12): 4810-4817. Diciembre de 2008. PMID 18812476. doi:10.1210/jc.2008-1518.

pharmazeutische-zeitung.de

«Typ-2-Diabetes: Albiglutid geht weltweit vom Markt» (en alemán). 2 de agosto de 2017.

wsj.com

«Glaxo Gets EU Marketing Approval for Diabetes Drug Eperzan».